CAMBRIDGE, MA, January 8, 2017 -- Aurora BioPharma, Inc. attends the 35th Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2017 at the Westin St. Francis Hotel in San Francisco, California.
Aurora BioPharma is a biotechnology company, revolutionizing the way we will treat cancer in the future. After 50 years of surgery, radiation and chemotherapy, cancer rates are still expected to double in the next 15 years. Medicine has a new weapon, genetically reprogramming the immune system into an elite killer army. Already three companies involved in genetically engineered Chimeric Antigen Receptor (CAR) T therapy, have been awarded Breakthrough Therapy Designation by the FDA for showing up to 90% remissions or nearly a "cure" in leukemia and other liquid tumors. Aurora has shown in a human Phase I/II trial with Glioblastoma, the most lethal brain cancer, nearly double the survival of a $1 Billion drug without the side effects.
The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry which brings together global industry leaders, emerging fast-growth companies, innovative technology creators, globally minded service providers, and members of the investment community.
Candace Cobos
Aurora BioPharma, Inc.
Tel: (617) 674-7718 - Fax: (617) 674-7701
candace.cobos@aurora-biopharma.com
SOURCE Aurora BioPharma, Inc.